Andrew J Bishop1, Gunar K Zagars1, Keila E Torres2, Kelly K Hunt2, Janice N Cormier2, Barry W Feig2, B Ashleigh Guadagnolo3. 1. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas. 2. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas; Department of Health Services Research, MD Anderson Cancer Center, Houston, Texas. Electronic address: aguadagn@mdanderson.org.
Abstract
PURPOSE: The purpose of this study was to investigate local control, survival outcomes, and complication rates of patients treated with aggressive surgery and radiation therapy (RT) for retroperitoneal sarcomas (RPS). METHODS AND MATERIALS: We reviewed the medical records of 121 consecutive patients treated for RPS with surgery and RT between 1965 and 2012. The most common histology was liposarcoma (n = 42; 35%). The median follow-up was 100 months (range: 20-467 months). Eighty-six patients (71%) were treated for initial presentation of RPS, and 35 patients (29%) presented with and were treated for RPS recurrence. RT was preoperative in 88 patients (73%; median dose: 50.4 Gy) and postoperative in 33 patients (27%; median dose: 55 Gy). RESULTS: Five-year local control and overall survival rates were 56% and 57%, respectively. Two factors were associated with higher risk of any intra-abdominal recurrence at 5 years: positive or uncertain margins (58% vs 30% for negative margins, P < .001; hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 1.6-4.8) and disease recurrence after previous resection (76% vs 31% for de novo RPS, P < .001; HR: 4.4; 95% CI: 2.5-7.5). The 10-year complication rate was 5%, and RT-related complications were associated with postoperative RT (P < .001) and RT dose of ≥ 60 Gy (P < .001). CONCLUSIONS: Intra-abdominal RPS recurrence continues to be a significant challenge despite the use of aggressive surgery and radiation therapy. Given the complications associated with postoperative radiation therapy, we recommend that preoperative radiation therapy is the preferred strategy when combined modality therapy is recommended.
PURPOSE: The purpose of this study was to investigate local control, survival outcomes, and complication rates of patients treated with aggressive surgery and radiation therapy (RT) for retroperitoneal sarcomas (RPS). METHODS AND MATERIALS: We reviewed the medical records of 121 consecutive patients treated for RPS with surgery and RT between 1965 and 2012. The most common histology was liposarcoma (n = 42; 35%). The median follow-up was 100 months (range: 20-467 months). Eighty-six patients (71%) were treated for initial presentation of RPS, and 35 patients (29%) presented with and were treated for RPS recurrence. RT was preoperative in 88 patients (73%; median dose: 50.4 Gy) and postoperative in 33 patients (27%; median dose: 55 Gy). RESULTS: Five-year local control and overall survival rates were 56% and 57%, respectively. Two factors were associated with higher risk of any intra-abdominal recurrence at 5 years: positive or uncertain margins (58% vs 30% for negative margins, P < .001; hazard ratio [HR]: 2.7; 95% confidence interval [CI]: 1.6-4.8) and disease recurrence after previous resection (76% vs 31% for de novo RPS, P < .001; HR: 4.4; 95% CI: 2.5-7.5). The 10-year complication rate was 5%, and RT-related complications were associated with postoperative RT (P < .001) and RT dose of ≥ 60 Gy (P < .001). CONCLUSIONS:Intra-abdominal RPS recurrence continues to be a significant challenge despite the use of aggressive surgery and radiation therapy. Given the complications associated with postoperative radiation therapy, we recommend that preoperative radiation therapy is the preferred strategy when combined modality therapy is recommended.
Authors: T Lehnert; S Cardona; U Hinz; F Willeke; G Mechtersheimer; M Treiber; C Herfarth; M W Buechler; M H M Schwarzbach Journal: Eur J Surg Oncol Date: 2009-01-12 Impact factor: 4.424
Authors: Nitesh N Paryani; Robert A Zlotecki; Erika L Swanson; Christopher G Morris; Stephen R Grobmyer; Steven N Hochwald; Robert B Marcus; Daniel J Indelicato Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-01 Impact factor: 7.038
Authors: Matthew T Ballo; Gunar K Zagars; Raphael E Pollock; Robert S Benjamin; Barry W Feig; Janice N Cormier; Kelly K Hunt; Shreyaskumar R Patel; Jonathan C Trent; Sam Beddar; Peter W T Pisters Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: Daniel P Nussbaum; Paul J Speicher; Brian C Gulack; Asvin M Ganapathi; Jeffrey E Keenan; Sandra S Stinnett; David G Kirsch; Douglas S Tyler; Dan G Blazer Journal: Surg Oncol Date: 2014-07-23 Impact factor: 3.279
Authors: William W Tseng; John E Madewell; Wei Wei; Neeta Somaiah; Alexander J Lazar; Markus P Ghadimi; Aviad Hoffman; Peter W T Pisters; Dina C Lev; Raphael E Pollock Journal: Ann Surg Oncol Date: 2014-04-07 Impact factor: 5.344
Authors: Anthony M Villano; Roberto J Vidri; Elaine T Vo; Stephanie H Greco; Krisha J Howell; Margaret von Mehren; Jeffrey M Farma Journal: Ann Surg Oncol Date: 2021-10-11 Impact factor: 5.344
Authors: A Montero; M Nuñez; O Hernando; E Vicente; R Ciervide; D Zucca; E Sanchez; M López; Y Quijano; M Garcia-Aranda; R Alonso; J Valero; X Chen; B Alvarez; P Fernandez-Leton; C Rubio Journal: Rep Pract Oncol Radiother Date: 2020-06-09
Authors: Randall J Brenneman; Nima Sharifai; Benjamin Fischer-Valuck; Comron Hassanzadeh; Jeffrey Guzelian; John S A Chrisinger; Jeff M Michalski; Peter Oppelt; Brian C Baumann Journal: Front Oncol Date: 2019-09-26 Impact factor: 6.244
Authors: Pippa F Cosper; Jeffrey Olsen; Todd DeWees; Brian A Van Tine; William Hawkins; Jeff Michalski; Imran Zoberi Journal: Radiat Oncol Date: 2017-12-08 Impact factor: 3.481